金融界2025年8月17日消息，广发医疗保健股票C(009163) 最新净值2.0428元，该基金近一周收益率 3.49%，近3个月收益率18.90%，今年来收益率28.79%。 来源：金融界 广发医疗保健股票C基金成立于2020年3月18日，基金经理吴兴武，截至2025年6月30日，广发医疗保健 股票C规模8.14亿元。 该基金股票持仓前十分别为：泽璟制药-U、科伦药业、百利天恒、新诺威、恒瑞医药、药明康德、东 阿阿胶、百济神州-U、开立医疗、惠泰医疗。前十持仓占比合计50.56%。 ...

该基金股票持仓前十分别为：恒瑞医药、泽璟制药-U、百济神州-U、新诺威、人福医药、华东医药、 开立医疗、奕瑞科技、潮宏基、联影医疗。前十持仓占比合计72.80%。 来源：金融界 金融界2025年8月17日消息，中海医疗保健主题股票A(399011) 最新净值1.1610元，该基金近一周收益率 3.38%，近3个月收益率11.31%，今年来收益率14.50%。 中海医疗保健主题股票A基金成立于2012年3月7日，基金经理梁静静，截至2025年6月30日，中海医疗 保健主题股票A规模4.93亿元。 ...

Group 1 - The core viewpoint of the article highlights the performance of the Huatai Fuhua Medical Service Flexible Allocation Mixed C Fund, which has shown significant returns in recent periods [1] - The fund's latest net value is 1.9560 yuan, with a weekly return of 3.06%, a three-month return of 34.90%, and a year-to-date return of 65.34% [1] - The fund was established on February 14, 2022, and as of June 30, 2025, it has a total scale of 1.069 billion yuan [1] Group 2 - The top ten stock holdings of the fund include companies such as Heng Rui Pharmaceutical, Ke Lun Pharmaceutical, and Hai Si Ke, with a total holding proportion of 68.66% [1] - The fund manager is Zhang Wei, who oversees the investment strategy and portfolio management [1]

Core Viewpoint - New Nuo Wei (300765) reported mixed financial results for the first half of 2025, with revenue growth but significant declines in net profit and profitability metrics [1][2]. Financial Performance - Total revenue reached 1.05 billion yuan, a year-on-year increase of 7.99% [1] - Net profit attributable to shareholders was -2.75 million yuan, a year-on-year decrease of 102.0% [1] - In Q2 alone, revenue was 578 million yuan, up 28.99% year-on-year, while net profit was 24.16 million yuan, down 58.33% [1] - Gross margin was 38.15%, down 12.87% year-on-year, and net margin was -17.8%, a decrease of 709.07% [1] - Total expenses (selling, administrative, and financial) amounted to 143 million yuan, accounting for 13.6% of revenue, an increase of 48.57% year-on-year [1] - Earnings per share were -0.0 yuan, a decrease of 102.05% year-on-year [1] Business Model and Historical Performance - The company's business relies heavily on research and marketing efforts, which require careful examination of underlying drivers [2] - Historical data shows a median Return on Invested Capital (ROIC) of 17.35%, with the worst year being 2024 at -6.79% [2] Cash Flow and Receivables - Cash flow metrics indicate a concerning situation, with cash and cash equivalents to current liabilities at only 96.59% and average operating cash flow to current liabilities at 8.37% over the past three years [2] - Accounts receivable have reached 882.29% of profit, suggesting potential liquidity issues [2] Market Position and Fund Holdings - Several funds have made significant changes in their holdings of New Nuo Wei, with notable new entries and reductions in positions among various funds [3]

Group 1 - The company has not distributed cash dividends, issued bonus shares, or converted reserves into share capital during the reporting period [2] - There has been no change in the controlling shareholder or actual controller during the reporting period [4] - The company does not have any preferred shareholders or related holdings during the reporting period [4] Group 2 - All directors attended the board meeting that reviewed the report [1] - The report is a summary derived from the full semi-annual report, and investors are encouraged to read the full report for a comprehensive understanding of the company's performance and future plans [1] - There are no significant matters reported during the period [4]

Group 1 - New Nuo Wei (300765.SZ) released its 2025 semi-annual report on August 16, 2025, with 71 institutional investors disclosing holdings of 1.194 billion shares, accounting for 85.00% of the total share capital [1] - The top ten institutional investors hold a combined 81.64% of shares, with a 1.63 percentage point increase compared to the previous quarter [1] Group 2 - In the public fund sector, seven funds increased their holdings, with a total increase of 1.04%, while 26 funds decreased their holdings, with a total decrease of 0.71% [2] - A total of 33 new public funds were disclosed this period, while 32 funds were not disclosed compared to the previous quarter [2] - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings by 0.36% [2]

Group 1: Company Performance - Shengyi Technology reported a net profit increase of 52.98% year-on-year for the first half of the year [1] - Dongfang Fortune achieved a net profit growth of 37% year-on-year, with total revenue reaching approximately 6.86 billion yuan, up from 4.94 billion yuan in the same period last year [3] - Dahua Technology's revenue for the first half of the year was 15.18 billion yuan, a 2.12% increase year-on-year, with a net profit of 1.80 billion yuan, up 1.91% [5] - Sanhe Tree's net profit increased by 107.53% due to improved gross margins and reduced expenses [14] - Lianhong New Science's net profit grew by 14.15% despite a 12.13% decline in revenue, indicating effective cost management [15] - Weichai Heavy Machinery reported a net profit increase of 52.62%, with revenue reaching 2.75 billion yuan, a 43.91% increase [19] Group 2: Industry Trends - The production of various copper-clad laminates reached 74.14 million square meters, a 7.86% increase year-on-year, indicating a growing demand in the electronics sector [2] - The aviation industry saw an increase in passenger capacity, with China Eastern Airlines reporting a 7.39% rise and China Southern Airlines a 6.66% rise in July [8][9] - The biopharmaceutical sector is witnessing significant growth, with companies like Xinnowei actively expanding into antibody drugs and mRNA vaccines, although facing challenges with increased costs [7] Group 3: Financial Dynamics - The total assets of Dongfang Fortune increased to approximately 355.28 billion yuan, up from 306.37 billion yuan year-on-year, reflecting enhanced capital strength [3] - The cash flow from operating activities for Dongfang Fortune was approximately 4.63 billion yuan, down from 10.25 billion yuan, indicating a need for improved cash management [3] - The gross margin for Xinnowei's biopharmaceutical segment decreased by 33.18%, highlighting pressures on profitability despite revenue growth [7]

Group 1 - The company reported a revenue of 1.05 billion yuan for the first half of the year, representing a year-on-year growth of 7.99% [1] - The net profit attributable to the company was -2.7461 million yuan, indicating a shift from profit to loss compared to the previous year [1] - The company invested 455 million yuan in research and development, accounting for 43% of its revenue, which is an 81% increase year-on-year [1]

证券日报网讯 8月15日晚间，新诺威发布公告称，公司第六届监事会第二十次会议审议通过了《关于公 司及其摘要的议案》等多项议案。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 8月15日晚间，新诺威发布公告称，公司第六届董事会第二十五次会议审议通过了《关于 公司及其摘要的议案》等多项议案。 ...